Other

Meet some of the OHE team at the International Health Economics Association (iHEA) 2019 World Congress in Basel, 13-17 July.

OHE staff recently attended the ISPOR annual conference in New Orleans. In this blog post, we share a selection of our presentations.

Meet some of the OHE team at the Spanish Health Economics Association (AES) 2019 conference in Albacete, 12-14 June.

‘Cascades of care’ have emerged as an attractive tool for assessing access to care for numerous chronic diseases. Dr Haacker will examine the use of cascades of care across diseases and populations, evaluate the use of cross-sectional targets in disease control strategies (e.g., the UNAIDS 90-90-90 targets), and address implications for cost-effectiveness analysis.

OHE wishes to recruit well-qualified, highly motivated and energetic economists, with particular strengths in the economics of health technology assessment, health care systems and/or the life sciences industry.

In September 2018, Professor Peter Smith delivered the 25th OHE Annual Lecture. The lecture is now available as a publication, which can be downloaded for free.

This year, the OHE team published 39 peer reviewed journal articles, gave 58 lectures and conference presentations, posted 22 in-house OHE publications on our website, and hosted 6 lunchtime seminars and our annual lecture.

Smith, P.

Monograph
January 2019

Debate about funding has highlighted the difficulty of persuading sceptics that the NHS is a good use of public finance. There is a widely held view – particularly in finance ministries and some sections of the media – that health systems such as the NHS are ‘black holes’, constantly demanding increased funding without concomitant returns to society.

OHE has published its report to the Charity Commission for the year 2017, its first full year as a registered charity.

OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia. The seminar will discuss the impact of the pan-Canadian Pharmaceutical Alliance “tiered pricing” framework (a flexible 'price-cap' regulation) on generic entry, the resulting drug expenditure levels from a drug plans’ perspective and the implications of price-capping policies on drug shortages.

Pages

Subscribe to RSS - Other